Added to YB: 2025-07-03
Pitch date: 2025-07-02
PYPD [bullish]
PolyPid Ltd.
+10.73%
current return
Author Info
The 10x Radar shares high-conviction small and microcap stock pitches with the potential to deliver multi-bagger returns. Sign up for the newsletter.
Company Info
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs.
Market Cap
$58.9M
Pitch Price
$3.54
Price Target
17.00 (+334%)
Dividend
N/A
EV/EBITDA
-1.47
P/E
-1.44
EV/Sales
N/A
Sector
Pharmaceuticals
Category
special_situation
PolyPid : The Biotech That Broke My Rules
PYPD: Biotech w/ successful Ph3 SHIELD II trial (58% SSI reduction, p<0.005) for surgical antibiotic gel D-PLEX100. $26.7M raised, cash through FDA approval. EU partner secured, US deal in late diligence. $1B initial TAM, potential $80M+ annual revenue at 15% penetration. 3x+ upside from $3.50, trading at fraction of $17/share DCF. Risks: regulatory, single-asset, warrants.
Read full article (8 min)